Market Newsdesk

PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) —

Driven Brands Holdings, Inc. (NASDAQ: DRVN) Class Action Survives Motion to Dismiss:

A securities fraud class action complaint against
Driven Brands Holdings, Inc. (NASDAQ: DRVN) has survived defendants, attempts to dismiss the complaint. Grabar Law Office is now investigating claims on behalf of long-term Driven Brands shareholders. The investigation concerns whether certain officers of the company have breached their fiduciary duties they owed to the company.

If you have held Driven Brands (NASDAQ: DRVN) shares continuously since prior to
October 27, 2021, you can
seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you. Visit https://grabarlaw.com/the-latest/driven-brands-shareholder-investigation/ or contact Joshua H. Grabar at [email protected] or call 267-507-6085 to learn more.

WHY: An underlying securities fraud class action complaint alleges that Driven Brands, through certain of its officers and directors, made numerous materially false and misleading statements and omissions pertaining to: (i) Driven Brands’ ability to efficiently and effectively integrate a high volume of acquired businesses, including statements related to the status of integrating its U.S. auto glass businesses; and (ii) the performance and competitive position of Driven Brands’ car wash business segment.

On February 20, 2025, a Federal Court determined that the allegations in the plaintiff’s underlying securities fraud class action complaint were adequately pleaded to survive defendants attempts to dismiss the complaint.

WHAT TO DO NOW: If you are a current Driven Brands shareholder who has held Driven Brands shares since prior to October 27, 2021, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/driven-brands-shareholder-investigation/, contact Joshua H. Grabar at [email protected] or call 267-507-6085. $DRVN #DrivenBrands

ModivCare, Inc. (NASDAQ: MODV):

Philadelphia, PA – Grabar Law Office is investigating claims on behalf of ModivCare, Inc. (NASDAQ: MODV) shareholders. The investigation concerns whether certain officers of ModivCare have breached the fiduciary duties they owed to the company.

Current ModivCare shareholders who have held ModivCare shares since prior to November 3, 2022, can seek corporate reforms, the return of funds back to the company,and a court approved incentive award – allat no cost to them whatsoever. To learn more visit:https://grabarlaw.com/the-latest/modivcare-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085.

Why: A recently filed securities fraud class action complaint alleges that ModivCare, Inc. (NASDAQ: MODV), through certain of its officers, misled the market to believe certain contracts used in its non-emergency medical transportation (“NEMT”) segment mitigated risks to its free cash flow. In reality, the Company’s free cash flow had deteriorated. When the truth began to reach the market, ModivCare’s stock price suffered significant declines, harming investors.

Specifically, Defendants failed to disclose that certain contracts used in ModivCare’s NEMT segment caused the Company’s free cash flow to deteriorate and that, as a result, (1) contract renegotiations and pricing accommodations negatively impacted the Company’s adjusted EBITDA; (2) the Company had insufficient liquidity; and (3) Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

What To Do Now:
Current ModivCare (NASDAQ: MODV) shareholders who have held ModivCare shares since prior to November 3, 2022, can seek corporate reforms, the return of funds back to the company,and a court approved incentive award – allat no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/modivcare-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085. #ModivCare $MODV

Monolithic Power Systems, Inc. (NASDAQ: MPWR):

Grabar Law Office is investigating claims on behalf of Monolithic Power Systems, Inc. (NASDAQ: MPWR) shareholders. The investigation concerns whether certain officers and directors of Monolithic have breached their fiduciary duties owed to the company.

Current Monolithic (NASDAQ: MPWR) shareholders who have held shares of the Company’s stock since prior to February 8, 2024, can seek corporate reforms, the return of funds back to the company, and potentially a court approved incentive award if appropriate, at no cost to them whatsoever. Click here to learn more: https://grabarlaw.com/the-latest/mpwr-shareholder-investigation/, contact Joshua Grabar at [email protected], or call us at 267-507-6085.

WHY: A recently filed securities fraud class action Complaint alleges that, Monolithic Power Systems, Inc. (NASDAQ: MPWR), via certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) Monolithic’s voltage regulator modules and power management integrated circuits were suffering from significant performance and quality control issues; (ii) these defects had, in turn, negatively impacted the performance of certain products offered by Nvidia in which such products were used; (iii) Monolithic had failed to adequately address and resolve known issues affecting the performance of the power management solutions Monolithic supplied to Nvidia; (iv) Monolithic’s relationship with Nvidia – the Company’s most important customer – had been irreparably damaged due to the significant performance and quality control problems affecting the products it supplied to Nvidia and Monolithic’s failure to adequately address such issues; and (v) as a result of the above, Monolithic was acutely exposed to material undisclosed risks of significant business, financial, and reputational harm.

WHAT YOU CAN DO NOW:
If you
have held Monolithic (NASDAQ: MPWR) shares since prior to February 8, 2024, you can seek
corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever.
Please visit

https://grabarlaw.com/the-latest/mpwr-shareholder-investigation/

, contact Joshua Grabar at

[email protected]

, or call us at 267-507-6085. #MonolithicPower #MPWR $MPWR

Virtu Financial Inc. (NASDAQ: VIRT) Class Action Survives Motion to Dismiss:

A federal securities fraud class action alleging that Virtu Financial Inc. (NASDAQ: VIRT), and certain of its officers failed to disclose to investors that it had improper safeguards in place and was not monitoring which of its employees were accessing the primary database containing sensitive trader information, has survived a motion to dismiss.

Virtu shareholders who have continuously held Virtu shares since prior to November 7, 2018, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. Learn more or join by clicking https://grabarlaw.com/the-latest/Virtu-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call 267-507-6085.

WHAT IS HAPPENING: Grabar Law Office is investigating claims on behalf of long-term Virtu (NASDAQ: VIRT) shareholders. The investigation concerns whether certain officers of the company have breached their fiduciary duties owed to the company. This investigation comes as a shareholder securities fraud class action has survived a motion to dismiss.

WHY: A securities fraud class action complaint alleges that Virtu Financial, via certain of its officers and directors, made false and/or misleading statements and/or failed to disclose that: (i) the Company maintained deficient policies and procedures with respect to its information access barriers; (ii) accordingly, Virtu had overstated the Company’s operational and technological efficacy as well as its capacity to block the exchange of confidential information between departments or individuals within the Company; (iii) the foregoing deficiencies increased the likelihood that the Company would be subject to enhanced regulatory scrutiny; and (iv) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

On March 17, 2025, a federal Court determined that key allegations were sufficiently pled to survive defendants’ motion to dismiss.

According to the Court’s Order, “essentially anyone at Virtu, including its proprietary traders” could directly access this material non-public information from at least January 2018 through April 2019, and to do so, Virtu traders only needed to use a “widely known and frequently shared username and password.”

“The court concludes that plaintiff’s ‘inference of scienter,’ [inference that defendants knew their statements or omissions were false or misleading or acted with reckless disregard for the truth] supported by circumstantial evidence of defendants’ reckless failure to inform its investors about the FS Database issue, is ‘cogent and at least as compelling as’ defendants’ opposing inference that they identified the FS Database issue, rectified it, and self-reported it to the SEC, while continuously updating the market on the fact of and substance of the resultant SEC investigation.”

WHAT YOU SHOULD DO NOW: If you are a current Virtu shareholder who has held Virtu stock since on or before November 7, 2018, you can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you.

If you
would like to learn more about this matter, you are encouraged visit

https://grabarlaw.com/the-latest/Virtu-shareholder-investigation/
, contact Joshua H. Grabar at [email protected] or call 267-507-6085. $VIRT #VirtuFinancial

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel:  267-507-6085
Email: [email protected]

MONROE TOWNSHIP, N.J., April 10, 2025 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT” or the “Company”), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced the signing of a reseller agreement with Grava Hydrographic Solutions LLC (“Grava Hydro”), a U.S.-based specialist in hydrographic and oceanographic equipment integration and services.

Under the agreement, Grava Hydro will expand the availability, sales, and support of OPT’s Unmanned Surface Vehicles (USVs), the Wave Adaptive Modular Vessels (WAM-V^®), throughout the United States.

Philipp Stratmann, CEO of Ocean Power Technologies, commented:
“Partnering with Grava Hydro represents a significant step in strengthening our domestic reseller network. Their expertise in hydrographic services and established customer relationships position them as an ideal partner to showcase and deploy our WAM-V technology in real-world environments.”

The agreement is part of OPT’s broader strategy to scale access to its marine robotics portfolio through trusted channel partners, delivering advanced capabilities for maritime data collection, survey operations, and coastal monitoring applications.

For more information about Ocean Power Technologies, please visit www.OceanPowerTechnologies.com. To learn more about Grava Hydrographic Solutions LLC, please visit www.GravaHydro.com.

ABOUT OCEAN POWER TECHNOLOGIES

OPT provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets, including Merrows™, which provides AI-capable seamless integration of Maritime Domain Awareness Systems across platforms. Our PowerBuoy^® platforms provide clean and reliable electric power and real-time data communications for remote maritime and subsea applications. We also provide WAM-V^® unmanned surface vehicles (USV’s) and marine robotics services. The Company’s headquarters is located in Monroe Township, New Jersey and has an additional office in Richmond, California. To learn more, visit www.OceanPowerTechnologies.com.

FORWARD-LOOKING STATEMENTS

This release may contain forward-looking statements that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as “may”, “will”, “aim”, “will likely result”, “believe”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions. These forward-looking statements reflect the Company’s current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates that could be inaccurate and subject to risks and uncertainties, including the potential success with our new partner, Grava Hydrographic Solutions LLC (“Grava Hydro”), the delivery of customers services and the conversion of potential customers to contracts and the realization of the potential revenue thereunder. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Forms 10-Q and 10-K and subsequent filings with the U.S. Securities and Exchange Commission for further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.

Contact Information

Investors: 203-561-6945 or [email protected]

Media: 609-730-0400 x402 or [email protected]

ROCHESTER, NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) — Syntec Optics Holdings, Inc. (“Syntec Optics” or the “Company”) (Nasdaq: OPTX), a leading provider of technology solutions for defense, communications, biomedical, and consumer end-markets, today announced securing follow-on orders of $2.1M for critical optics that integrate into the next-generation military scopes.

Syntec Optics previously announced the creation of a dedicated manufacturing cell at the facility and engineering efforts to scale for advanced optics. The new scopes integrate several advanced technologies, including a variable magnification optic, laser rangefinder, visible and infrared lasers, a digital display overlay, and several other sensing and calculating abilities.

Syntec’s mission-critical optics are scheduled to be delivered through 2026. Orders will likely increase in the following years and are anticipated to last over a decade.

Syntec Optics team uniquely produces intricate optics using advanced manufacturing techniques that enable the Army to take full advantage of its next-generation equipment as it attempts to modernize half-century-old equipment. The new scope, where Syntec’s optics are integrated, is like a computer calculating range, ballistics, atmospherics, directional information, digital overlay, and wireless features, and it can also link to the Army’s new smart goggles.

About Syntec Optics

Syntec Optics Holdings, Inc. (Nasdaq: OPTX), headquartered in Rochester, NY, is one of the largest custom and diverse end-market optics and photonics manufacturers in the United States. Operating for over two decades, Syntec Optics runs a state-of-the-art facility with extensive core capabilities of various optics manufacturing processes, both horizontally and vertically integrated, to provide a competitive advantage for mission-critical OEMs. Syntec Optics recently launched new products, including Low Earth Orbit (LEO) satellite optics, lightweight night vision goggle optics, biomedical equipment optics, and precision microlens arrays. To learn more, visit www.syntecoptics.com.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended, including certain financial forecasts and projections. All statements other than statements of historical fact contained in this press release, including statements as to the transactions contemplated by the business combination and related agreements, future results of operations and financial position, revenue and other metrics, planned products and services, business strategy and plans, objectives of management for future operations of Syntec Optics, market size, and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “plan,” “targets,” “projects,” “could,” “would,” “continue,” “forecast” or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are subject to risks, uncertainties, and other factors (some of which are beyond the control of Syntec Optics), which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are based upon estimates, forecasts and assumptions that, while considered reasonable by Syntec Optics and its management, as the case may be, are inherently uncertain and many factors may cause the actual results to differ materially from current expectations which include, but are not limited to: 1) risk outlined in any prior SEC filings; 2) ability of Syntec Optics to successfully increase market penetration into its target markets; 3) the addressable markets that Syntec Optics intends to target do not grow as expected; 4) the loss of any key executives; 5) the loss of any relationships with key suppliers including suppliers abroad; 6) the loss of any relationships with key customers; 7) the inability to protect Syntec Optics’ patents and other intellectual property; 8) the failure to successfully execute manufacturing of announced products in a timely manner or at all, or to scale to mass production; 9) costs related to any further business combination; 10) changes in applicable laws or regulations; 11) the possibility that Syntec Optics may be adversely affected by other economic, business and/or competitive factors; 12) Syntec Optics’ estimates of its growth and projected financial results for the future and meeting or satisfying the underlying assumptions with respect thereto; 13) the impact of any pandemic, including any mutations or variants thereof and the Russian/Ukrainian or Israeli conflict, and any resulting effect on business and financial conditions; 14) inability to complete any investments or borrowings in connection with any organic or inorganic growth; 15) the potential for events or circumstances that result in Syntec Optics’ failure to timely achieve the anticipated benefits of Syntec Optics’ customer arrangements; and 16) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in prior SEC filings including registration statement on Form S-4 filed with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Syntec Optics does not give any assurance that Syntec Optics will achieve its expected results. Syntec Optics does not undertake any duty to update these forward-looking statements except as otherwise required by law.

For further information, please contact:

Tim Bechtold 

Investor Relations

[email protected]

SOURCE: Syntec Optics Holdings, Inc. (Nasdaq: OPTX)

Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer

Led development of multiple clinical candidates from conception through IND and early clinical development

Vast experience in technology licensing, correlation from “bench to bedside” and back and execution of scientific strategy

SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B. Trager, Ph.D. to its Scientific Advisory Board (“SAB”).

Dr. Trager is a well-established biotechnology leader deeply versed in the development and application of cellular therapies for cancer. He brings to Senti Bio over 25 years of technical expertise, strategic execution and development of novel cellular and biologic therapies. In addition to his industry positions, he also serves as an advisor for the Shoreline Community College Immunotherapy Biohub and SPARK at Stanford. Over the course of his career, he has contributed to nearly 50 publications, abstracts and patents.

“James brings a wealth of leadership experience and scientific expertise to our SAB, that we believe will be invaluable as we continue to advance the development of our potential best-in-class oncology programs. We look forward to leveraging his decorated career in research and product development moving forward,” says Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.

“Senti Bio’s Logic Gating technology has demonstrated encouraging potential to address the central challenge in oncology which is to precisely distinguish cancer vs healthy cells and maximize therapeutic potential. Additionally, the data seen to date from the SENTI-202 program for AML has shown a lot of promise as a potential treatment option in this indication where there remains significant unmet medical need. I am excited to be joining the Senti Bio SAB and look forward to working closely with the team to advance this important technology and pipeline of product candidates,” added Dr. Trager.

Dr. Trager formerly served as the Chief Scientific Officer of Nkarta Therapeutics where he led the development of multiple discovery assets through IND and the creation of a pipeline of CAR NK product opportunities. Prior to his role at Nkarta, Dr. Trager held a number of increasing roles and responsibilities at Dendreon Pharmaceuticals, Inc., most recently having served as Vice President of Research and Product Development, where he was responsible for product and biomarker development development activities, supporting the late stage development of sipuleucel-T through clinical study, approval, and commercialization. Prior to that, Dr. Trager served as a Senior Scientist at Geron Corporation, where he was part of the team that cloned human telomerase, and enabled the manufacture and clinical development of a telomerase inhibitor. Across his career, he managed and integrated the efforts of over 100 scientists, engineers and technicians contributing to the invention and development of multiple cell therapies.

Dr. Trager holds a BA from St. John’s College in Santa Fe New Mexico and his Ph.D. in Molecular Biology and Biochemistry from the University of California at Berkeley.

About Senti Bio

Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration. Senti Bio’s wholly-owned pipeline includes off-the-shelf CAR-NK cells, outfitted with Gene Circuits, to target challenging liquid and solid tumor indications. Senti Bio’s lead program SENTI-202, a Logic Gated CD33 and/or FLT3-targeting hematologic cancer therapeutic candidate, is currently enrolling patients in a Phase I clinical trial. Senti Bio has also preclinically demonstrated that its Gene Circuits can function in T cells, for example Logic Gates that enable selective targeting of solid tumors. Additionally, Senti Bio has preclinically demonstrated the potential breadth of Gene Circuits in other cell and gene therapy modalities, diseases outside of oncology, and continues to advance these capabilities through partnerships.

Forward-Looking Statements

This press release contains certain statements that are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally are identified by the words “believe,” “could,” “predict,” “continue,” “ongoing,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” “forecast,” “seek,” “target” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations of Senti Bio’s management and assumptions, whether or not identified in this document, and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding future events, including the success of our future clinical development and ability to create shareholder value. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Senti Bio. Many factors could cause actual future results to differ materially from the forward-looking statements in this document, including but not limited to: (i) changes in domestic and foreign business, market, financial, political and legal conditions, (ii) changes in the competitive and highly regulated industries in which Senti Bio operates, variations in operating performance across competitors, changes in laws and regulations affecting Senti Bio’s business, (iii) the ability to implement business plans, forecasts and other expectations, (iv) the risk of downturns and a changing regulatory landscape in Senti Bio’s highly competitive industry, (v) risks relating to the uncertainty of any projected financial information with respect to Senti Bio, (vi) risks related to uncertainty in the timing or results of Senti Bio’s clinical trial initiation and the progress of clinical trials, patient enrollment, and GMP manufacturing activities, (vii) Senti Bio’s dependence on fourth parties in connection with clinical trial startup, clinical studies, and GMP manufacturing activities, (viii) risks related to delays and other impacts from macroeconomic and geopolitical events, increasing rates of inflation and rising interest rates on business operations, (ix) risks related to the timing and utilization of Senti Bio’s grant from CIRM and net proceeds of the PIPE financing, and (x) the success of any future research and development efforts by Senti Bio. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Senti Bio’s most recent Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission (“SEC”), and other documents filed by Senti Bio from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements in this document. There may be additional risks that Senti Bio does not presently know, or that Senti Bio currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements in this document. Forward-looking statements speak only as of the date they are made. Senti Bio anticipates that subsequent events and developments may cause Senti Bio’s assessments to change. Except as required by law, Senti Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/51b2998d-5e06-4e0c-90f4-5c75ab43f03e

PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) — Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) on behalf of purchasers of Zynex securities between March 13, 2023 through March 11, 2025, inclusive (the “Class Period”).

Investor Deadline: Investors who purchased or acquired
Zynex
securities during the Class Period may, no later than
MAY 19, 2025
, seek to be appointed as a lead plaintiff representative of the class.

To learn your rights,




CLICK HERE




.

Zynex, headquartered in Englewood, CO, is a medical device company that makes electrotherapy devices for pain management and rehabilitation.

According to the lawsuit, Defendants failed to disclose to investors that: (1) Zynex shipped products, including electrodes, in excess of demand; (2) as a result, Zynex was able to inflate its revenue; (3) the Company’s practice of filing false claims drew scrutiny from insurers, including Tricare; and (4) thus, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government.

To learn your rights or for more information,




CLICK HERE




or please contact Berger Montague: Andrew Abramowitz at




[email protected]




or (215) 875-3015, or Peter Hamner at




[email protected]


.

A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Communicating with any counsel is not necessary to participate or share in any recovery achieved in this case. Any member of the purported class may move the Court to serve as a lead plaintiff through counsel of his/her choice, or may choose to do nothing and remain an inactive class member.

Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contact:

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]  

Peter Hamner
Berger Montague PC
[email protected]